Remdesivir Versus Standard-of-Care for Severe Coronavirus Disease 2019 Infection: An Analysis of 28-Day Mortality.

Susan A OlenderTheresa L WalunasEsteban MartinezKatherine K PerezAntonella CastagnaSu WangDax KurbegovParag GoyalDiego RipamontiBindu BalaniFrancesco G De RosaStéphane De WitShin-Woo KimGeorge DiazRaffaele BrunoKathleen M MullaneDavid Chien LyeRobert L GottliebRichard H HaubrichAnand P ChokkalingamGeorge WuHelena Diaz-CuervoDiana M BrainardI-Heng LeeHao HuLanjia LinAnu O OsinusiJose I BernardinoMarta Boffito

Published in: Open forum infectious diseases (2021)

Remdesivir was associated with significantly higher rates of day 14 clinical recovery, and lower day 28 mortality, compared with standard-of-care treatment in hospitalized patients with COVID-19. These data, taken together, support the use of remdesivir to improve clinical recovery and decrease mortality from SARS-CoV-2 infection.

Keyphrases

coronavirus disease
cardiovascular events
healthcare
palliative care
risk factors
quality improvement
respiratory syndrome coronavirus
electronic health record
cardiovascular disease
early onset
big data
machine learning
type diabetes
affordable care act
drug induced